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It is a common practice in contemporary medicine to follow stringently the scientific method in the
process of validating efficacy and effectiveness of new or improved modes of treatment intervention.
It follows that these complementary or alternative interventions must be validated by stringent research
before they can be reliably integrated into Western medicine. The next decades will witness an increas-
ing number of evidence-based research directed at establishing the best available evidence in comple-
mentary and alternative medicine (CAM). This second paper in this lecture series examines the
process of evidence-based research (EBR) in the context of CAM. We outline the fundamental prin-
ciples, process and relevance of EBR, and its implication to CAM. We underscore areas of future
development in EBR. We note that the main problem of applying EBR to CAM at present has to do
with the fact that the contribution of EBR can be significant only to the extent to which studies used
in the process of EBR are of good quality. All too often CAM research is not of sufficient quality to
warrant the generation of a consensus statement. EBR, nevertheless, can contribute to CAM by identi-
fying current weaknesses of CAM research. We present a revised instrument to assess quality of the
literature.
Keywords:evidence-based research–systematic review –consolidated standards of randomized trials –
Markov model – complementary and alternative medicine
Evidence-Based Research
Aims and Caveats
Evidence-based research (EBR) in medicine, as conceived by
A. Cochrane (1909–88), must not to be confused with medi-
cine based on research evidence. EBR is a research movement
in the medical sciences based upon the application of the sci-
entific method. It seeks the conscientious, explicit and judi-
cious identification, evaluation and use of the best evidence
currently available. It is a systematic process whose purpose
is to congeal the best available research findings with patient
history and laboratory test results in order to optimize the
process of making decisions about the care of each individual
patient. Medicine based on the evidence, in contrast, is the tra-
ditional approach to medical treatment. It rests on long-
established existing medical traditions, supplemented by indi-
vidual pieces of evidence provided by the medical exam (e.g.
history, test results), which may or may not have undergone
adequate or sufficient scientific scrutiny (1–5).
The debate over evidence-based medicine versus medi-
cine based on the evidence is complex, and far from being
abated (4,6). It argues, for example, that medical doctors
have depended upon reliable research evidence for their treat-
ment ever since the rise of modern medicine (6). The EBR
movement does not dispute that. It underscores the fact that
research in the health sciences is advancing at such a fast
pace that the body of evidence must be systematically
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A second argument stems from the fact that, in some
domains of the health sciences at least, the research evidence
can be deficient, inadequate or unreliable, and that therefore
medicine must rest on traditional modes of interventions
even if they have not been validated by research (6). The
EBR movement underscores in this context that it is through
the systematic evaluation of the research methodology,
designs and data analysis that it becomes possible to identify
research deficiencies in given clinical domains, which then
serve to improve quality of research evidence (4,5,7,9).
A third important point of argument suggests that pro-
ponents of EBR make a conceptual error by grouping know-
ledge derived from clinical experience and physiological
rationale under the heading of the best available evidence,
and further compound errors by developing hierarchies of
evidence. That is to say, lack of evidence and lack of benefit
are not the same, and the more data are pooled and aggregated
the more difficult it becomes to compare patients in studies
with the individual patient in front of the doctor. Clinicians
need to incorporate knowledge from several distinct areas
into medical decision, including empirical evidence, experi-
ence, physiological principles, patient needs, wants and cover-
age, and professional values (6). This latter question is
particularly relevant to an unbiased appreciation of EBR, and
the remainder of this paper responds to this question, with
emphasis on complementary and alternative medicine (CAM).
Consensus of the Best Available Evidence
Certain caveats plague the practical application of EBR in a
day-to-day medical practice (2–4,10), particularly in the con-
text of certain CAM protocols, such as acupuncture (9). A
few salient among these are listed in Table 1. It is also true,
however, that the fundamental purpose of EBR is to validate
modern medical practice, and consequently the evolution
and establishment of evidence-based medical practice is a
sine qua non for medicine in the 21st Century (7).
EBR contributes to the validation of medical practice by sys-
tematically evaluating strength of available evidence (2,4,5,7).
The purpose of EBR is not to group knowledge derived from
clinical experience and physiological rationale under the
heading of best available evidence (6), nor is it to develop
hierarchies of evidence (6). Quite the contrary, EBR aims at
generating a consensus statement that summarizes the outcome
of a process of systematic evaluation of the literature. The
statement provides ipso facto scientific validation of the best
available evidence thus generated from all of the available
research and of the clinical decision-making process
(2,7,8,10).
The consensus statement is the outcome of the process of the
systematic review and evaluation of all of the available evid-
ence. It presents inferences, summative evaluations and con-
clusive narrative synthesis of the findings. It discusses
problems pertaining to presentation and relevance of findings,
including whether or not key elements of each study are clearly
displayed, magnitude of findings is statistically significant and
the findings are homogeneous or heterogeneous. The con-
sensus statement also addresses concerns of clinical relevance,
of the validity of the integration process (e.g. inclusion and
exclusion criteria, comprehensive search strategy) and of the
rigor of the evaluation process (e.g. quality of evidence rating,
cf. double arrow in Fig. 1). The focus of the consensus state-
ment pertains to sensitivity and specificity analyses, and
whether or not the overall findings suggest an overall net bene-
fit for patients. To assess the quality control of the process of
integration, a third independent reviewer, ‘standardized’ to
the other readers (11), usually is engaged to assess systematic-
ally the studies’ validity and statistical and clinical signific-
ance. The consensus statement includes a discussion of those
issues as well. In brief, the consensus statement discusses the
quality of the evidence on each individual report, as well as a
bottom-line statement, a cogent synthesis of the research,
explicating the best available evidence (2–5,7).
The panel of experts who performs the systematic review
drafts the consensus statement. It is then presented and dis-
cussed in an open forum to patient group advocates and the
general public. The panel finalizes the consensus statement
in executive session, and the final report is generated. Some
Table 1. Fundamental limitations of EBR
  Overwhelming scope of the scientific information.
  High stringency of scientific research.
  Challenge to maintain up-dated research evaluation.
  Demands of clinical relevance versus statistical significance.
  Different views on clinical relevance (e.g. levels of clinical significance
based on categories, such as tangible versus intangible benefits, size of
treatment effect).
  Subjectivity in evaluation of internal versus external validity threats.
  Lack of clinical use and acceptability through clinical testing.
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Figure 1. The process of evidence-based research in complementary and
alternative medicine.
4 Evidence-based complementary and alternative medicinereview groups (e.g. the Cochrane Group) insist upon the need
for regular updates of the consensus statement (usually every
6 months), some others do not (e.g. the National Institutes of
Health, NIH).
Developing the Consensus Statement
The overall report generated at the completion of the EBR
process evidently goes well beyond the routine narrative liter-
ature review. It is a systematic review of all of the available
research evidence—good and bad (on criteria of research
design, methods and data analysis)—which culminates in the
consensus statement. The systematic process of critical evalu-
ative research of the available evidence follows the scientific
method (2,5,7). It is not aimed at pooling and aggregating
data across studies indiscriminately. EBR aims at determining
the quality of each report, based on stringent criteria of
research methodology, design and data analysis. Reports
deemed acceptable are used in the second phase of the process
that synthesizes the evidence by means of meta-analytical
techniques, and generates a bottom-line, which serves to aid
clinical decision-making (1,12).
The goal is clearly not to compare the patients in the studies
with the individual patient in front of the doctor (6). It is to
apply best of what research literature provides for direct
benefit of patients in front of doctor (4,5,10).
Clinical research in CAM in the 21st Century requires the
stringent, rigorous and systematic approach provided by
EBR. The paucity of CAM specific validated measures or
use of more generic measures will impact directly on the
EBR process: the significant current debate around what
outcomes should be measured and how they are measured is
not abated (13). The future of clinical and translational
research in CAM lies in the systematic evaluation of
research evidence in treatment intervention for patients and
in judicious and timely generation of the consensus statement
(7,9,14,15).
Research on Research
The Process of EBR
The flow of EBR, outlined in Fig. 1, is applied to the per-
formance of systematic reviews, which encompass all avail-
able literature. Best case studies in EBR entail performance
of the process of EBR with a random sample of available
literature. The scientific process of EBR is dependent upon
essential tools and methods for the reliable qualitative and
quantitative critical reading of individual papers in the context
of the best-case studies and, more broadly, of systematic
reviews. This figure illustrates that the end-product, the
bottom-line of EBR, is the generation of a consensus state-
ment, as discussed above. This figure also indicates a recip-
rocal feedback between the box of tools for EBR and the
consensus statement. This is so because the complete process
of EBR employs a set of selected and specified tools and
instruments of research, which generates the analysis of
findings, which is presented and discussed in the consensus
statement. The consensus statement thus should ideally
include a discussion of strengths, weaknesses, limitations and
caveats of these tools and instruments. The double arrow is
meant to represent this reciprocal feedback by which the gen-
eration of the consensus statement is derived from the use of
certain tools of research, and provides an evaluative compon-
ent with respect to if and how these tools ought to be
perfected for future evidence-based research.
EBR is a Form of Critical Research on Research that
Follows the 5-Step Scientific Process
(i) It begins by stating the research question, which com-
prises the PIC/PO question. The question defines the
patient population being examined and the interven-
tions being considered (e.g. conventional treatment
versus conventional treatment supplemented with
CAM), whether the interventions are compared or
studied from the longitudinal perspective and predic-
tions are being drawn, and specifies the outcome of
interest (5,7).
(ii) The second step involves methodological issues,
including the sampling and accessing of the research
literature, and the tools for critical analysis of the
reports (5,7). The sampling process requires extensive
library search of published materials (e.g. clinical
trials) and additional individual communications
with individual researchers and authors, when further
information is needed.
(iii) The sample is critically evaluated using stringent
standards [e.g. the Consolidated Standards of Ran-
domized Trials (CONSORT) (16,17)]. In the case of
acupuncture, the STRICTA norms (Standards for
Reporting Interventions in Controlled Trials of
Acupuncture) are further recommended (9). Reliable
and valid instruments {e.g. Timmer scale, Jadad
scale, Wong [cf. Appendix 1; (18)], Linde internal
validity scales; for a review, see (5)} are used for
this purpose. Alternative means [e.g. GRADE,
ASSERT; for a review, see (19)] are also utilized
and converge with the former in quantifying levels
of quality of the research and of levels of significance
of evidence.
(iv) The data from separate reports are pooled, analyzed
for acceptability (20), and when appropriate, utilized
in meta-analysis or meta-regression analyses for the
generation of an overarching statistical significance
(5,12,21,22). EBR data can also be analyzed by Indi-
vidual Patient Data (IPD) (23) or Number Needed to
Treat (NNT) analyses (3). These formats differ from
traditional modes of statistical analysis in that they
pertain to analysis of data of individual patients as
opposed to traditional analysis of data from groups
of patients. In general, moreover, EBR data are best
eCAM 2006;3(1) 5analyzed by means of Bayesian, rather than the tradi-
tional Fisherian statistics, in order to interpret data
from research in the context of statistical significance
and clinical relevance.
(v) The last step is a cumulative synthesis, which
summarizes the process and the findings. The con-
sensus statement must be coherent with and reflect
the best available evidence with respect to the stated
PIC/PO question [cf. Appendix 2 adapted from (7)]
(2,10,24,25).
Merits and Strengths of EBR in Clinical
Decision-Making
The merit and strength of EBR lie not only in the rigor of its
scientific method but also in the validity of its product, the con-
sensus statement. EBR and the outcomes it generates have dir-
ect applications and extensions to immediate needs of patients,
to the best available evidence for intervention and cost
(2,7,8,10). A well-constructed consensus statement presents a
cost-effectiveness analysis, which is a process of decision ana-
lysis that incorporates risks as well as cost. This is achieved by
a step approach that generally involves an evaluation of
whether or not the problem was framed in a clinically relevant
manner (i.e. PIC/PO question), of the validity of integrated
information (i.e. critical evaluation of the literature), the rigor
of process of integration [i.e. inclusion & exclusion criteria
of reliable versus unreliable (acceptable versus unacceptable)
evidence] and of the presentation and quality of the findings
(i.e. summative evaluation) (7).
The relevant findings in this cost-effectiveness analysis are
most often expressed as the incremental cost-effectiveness
between conventional treatment alone and conventional treat-
ment supplemented by complementary alternative treatments.
The incremental ratio, that is the difference in costs between
the two strategies divided by the difference in effectiveness
between the two strategies, is often presented as well
(Fig. 2) (5).
Figure 2 illustrates that following the scientific process of
EBR and generation of the consensus statement, the overall
clinical relevance is assessed, implemented and evaluated by
the clinician. Effectiveness and utilities data are estimated
(e.g. Markov model; cf. Appendix 3: the Markov Process) to
aid the final clinical decision-making process. (5,10).
The EBR process evaluates each competitive strategy, usu-
ally by means of the Markov model-based decision tree. This
approach permits to model events that may occur in the future
as a direct effect of treatment or as a side effect. The model
produces a decision tree that cycles over fixed intervals in
time, and incorporates probabilities of occurrence. Even if
the difference between the two treatment strategies appears
quantitatively small, the Markov model outcome reflects the
optimal clinical decision, because it is based on the best pos-
sible values for probabilities and utilities incorporated in the
tree. The outcome produced from the Markov decision ana-
lysis is generally obtained by means of the sensitivity analysis
to test the stability over a range probability estimates, and thus
reflects the most rational treatment choice (25,26).
EBR in the Context of CAM
In summary, the performance of EBR is a science in its own
right. The integration of the EBR paradigm in CAM has
already been recognized (7,14,15,27). Undoubtedly, EBR
will increasingly play an important role in distinguishing
appropriate versus non-appropriate (i.e. acceptable versus
non-acceptable; see below) CAM-based intervention in the
future. Clinical and translational CAM research in the 21st
century will rely upon the systematic evaluation of the
research evidence. Progress in EBR of CAM must strive along
these dimensions.
Tools and Protocols
First, the field of EBR needs to refine and finalize its tools and
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Figure 2. Algorithm of the process of applying research evidence in clinical decision making [adapted from (5)].
6 Evidence-based complementary and alternative medicineevaluation of the research methodology, design and data
analysis. Depending upon the tools utilized to evaluate the
scientific literature, scores are obtained about the complete-
ness and quality of research methodology, and design and stat-
istical handling of the findings are generated (SESTA,
systematic evaluation of the statistical analysis). Appendix 1
offers a revision of the Wong scale (18), followed by a detailed
highlight of the SESTA paradigm. Utilization of this scale
and of SESTA permit the qualitative and quantitative evalu-
ation of the research methodology, design and data analysis.
Quantification yields values that are analyzed by acceptable
sampling statistical protocols to establish whether or not the
sample of research reports studied by means of the evidence-
based process has met criteria of acceptability to produce
meta-analyses and reliable over-arching inferences.
This protocol does not seek to estimate the quality of the lot,
which would be equivalent to evaluating the quality of the
search literature process, but rather to estimate its acceptability
(20). Acceptance sampling generates information based either
on the attributes (i.e. nominal variable: acceptable based on a
set of rigorously set criteria versus not acceptable) or on the
characteristics of the identified information (i.e. continuous
variable assessed along some interval scale).
Case in point, a best-case study we conducted of the use
of music therapy as an alternative intervention to relieve anxi-
ety generated reliable data, which permitted demonstration
of the relative consistencies and inconsistencies in research
methodology, research design and data analysis across the
papers evaluated in the systematic review. The data could
be used to quantify and to underscore strengths and deficien-
cies of this specific domain of the CAM literature. This best
case study on music therapy as an alternative mode of inter-
vention for anxiety revealed that the two weakest domains of
that research literature pertain to information provided about
the number needed to treat and statistical analysis of data.
Another overwhelming weakness of this literature relates to
the tools of measurement. Acceptable sampling analysis
of these findings indicated that these three deficiencies
were statistically significant (Greenhouse-Geisser F ¼ 7.58,
P < 0.0001; Scheffe ´, P < 0.05). Of borderline significance
(P < 0.1) was the domain of research that pertains to the
establishment of statistical and clinical significance.
In brief, this analysis permits to evaluate strength and
stringency of music therapy as an alternative mode of inter-
vention for anxiety. It established that 90% of this literature
has appropriate research methods, design and data analysis,
with an overall score (21.09 ± 3.14) within the 95% confid-
ence interval of top rating. It also identified the principal
domains of weakness within this CAM literature (e.g. number
needed to treat information, statistical analysis of the
data, tools of measurements), which must be corrected in
future research. Lastly, this analysis underscored the fact
that the literature on music therapy for anxiety has to date
failed to make a compelling statement of relationship
between statistical significance of findings and their clinical
relevance.
Future Analyses in EBR
For the future, it is important to realize that these research
quality-rating scales lead to the possibility of an evaluation
following the principles of Boolean logic. That is to say, if,
for instance, the first two questions (i.e. study question and
study outcome) are evaluated to be congruent, then a conjunct-
ive logic association is produced (study question ¼ 1, study
outcome ¼ 1, conjunction ¼ 1). This outcome then leads to
evaluation of whether or not the measures and design are in
fact congruent with the study question and outcome as repor-
ted. A conjunctive logic association furthers the process to
examine SESTA, which itself can be reduced to a series of
Boolean arguments. The outcome of the process, which we
are now in the process of automating in a computer-assisted
software, is either 1 (report overall acceptable based on criteria
of research methods, design and analysis) or 0 (report unac-
ceptable). Zeros appear in the Boolean process whenever a
disjunction is attained (e.g. design in congruent forstated study
question and study outcome). Both acceptable and unaccept-
able reports are integrated into the consensus statement. The
latter contributes in formulating recommendations for the
best available evidence for clinical decision-making, whereas
unacceptable reports are discussed in terms of their deficien-
cies and the information they may provide for further improve-
ment of research.
Evaluations of EBR such as these hold considerable promise
to strengthen quantification of the EBR process, and thus to
enhance considerably the value of the consensus statement.
This will contribute to the role and valence of EBR in provid-
ing informed and scientifically supported statements of accept-
ability for CAM.
Practicality and Dissemination of EBR in CAM
The dissemination of EBR in CAM must become more prac-
tical and contextual, in order for it to become intelligible to
providers, to patient groups and to insurance carriers. This is
necessary to facilitate its integration into every-day medical
decision-making and treatment (5,10,28). This will require
concerted efforts to expand and to deepen education about
knowledge of the process, outcome and practical uses of
EBR (24), and to utilize EBR in daily procedures and protocols
in order to shift from ‘trade-professions’ to ‘evidence-based
professions’. Existing meta-analyses and systematic reviews
(e.g. Cochrane reports) should be catalogued, reviewed and
summarized, and their findings should be effectively dissemin-
ated among providers, patients and insurance providers (17).
EBR Specialist for Benefiting CAM Practice
Lastly, the establishment of an ‘EBR specialist’ must be seri-
ously considered (3), who can work from within the medical
establishment to retrieve, read, evaluate and present the best
available evidence with respect to complementary and altern-
ative modes of intervention. This specialist will contribute to
the establishment of criteria of EBR and of evidence-based
eCAM 2006;3(1) 7clinical practice guidelines that will require these to be valid-
ated, assessed and monitored by a network of professional
EBR practitioners in CAM under the auspices of national and
international professional, medical and CAM associations.
The EBR specialist will contribute to the process of review,
assessment and evaluation of consensus statements, as well as
of complaint for malpractice based on evidence-based clinical
practice guidelines. This latter point is particularly important
in the context of CAM interventions, which are often prone
to distrust by the Western medical establishment because of
the lack of substantiating research evidence. The EBR special-
ist will endeavor, for instance, at disseminating findings of sys-
tematic reviews on CAM through the Internet to make EBR
easy to access, easy to understand and easy to use. This
will require dissemination of consensus statements in lay and
foreign languages.
In summary, the concerted efforts we have outlined hold the
promise of increasing acceptance and dissemination of CAM
treatment modalities for the ultimate benefit of patients
(29,30). This endeavor can only be attained by stringent adher-
ence to the scientific method in EBR over the next decades (7).
EBR can be a powerful tool for identifying the questions for
which no satisfactory evidence exists—a very common situ-
ation in CAM. Nevertheless, it must also be recognized that
the main problem of applying EBR to CAM has to do with
the fact that EBR will be useful in this context of science
only to the extent to which the studies used in the process of
EBR are of good quality, comparable and reliable. Unfortu-
nately, all too often studies on CAM modalities are still today
of inferior quality and preclude a sound EBR approach.
Acceptable analysis of the type described above, and the use
of certain EBR instruments, will serve to identify the weak-
nesses of CAM research.
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Appendix 1: Wong Scale (Revised)
1. What
A. What is the research question/purpose/outcome sought?
Is the stated purpose tested and measured correctly?
2–3 sentences
8 Evidence-based complementary and alternative medicineScore: 1 ¼ inadequate, raise doubts and concern,
2 ¼ adequate, but incomplete, 3 ¼ fine
B. What are the findings, how are they presented? Do the
findings respond to the stated purpose/outcome sought?
2–3 sentences
Score: 1 ¼ inadequate, raise doubts and concern,
2 ¼ adequate, but incomplete, 3 ¼ fine
C. What is the clinical significance of the findings, and
what is their statistical significance? Do the findings mean
anything anyway...research-wise or clinic-wise?
2–3 sentences
Note: issues about risk-to-benefit ratio, cost-to-benefit ratio;
also note issues about P-values versus a level
Score: 1 ¼ inadequate, raise doubts and concern,
2 ¼ adequate, but incomplete, 3 ¼ fine
2. Who
A. What was the sample tested,is the sample representative
of the population under study, of your patients?
2–3 sentences
Note: issues of sampling and related threats to external valid-
ity (i.e. selection of sample representative of population under
study) and to internal validity [i.e. concerns of maturation,
mortality (i.e. drop-out), history]. Note that this question
includes the drop-out query of the Jadad scale.
Score: 1 ¼ inadequate, raise doubts and concern,
2 ¼ adequate, but incomplete, 3 ¼ fine
B. Are numbers presented in the paper that you can trust,
and would that permit you to compute the Number Needed
to Treat (NNT)? List experimental group event rate (EER)
and control group event rate (CER), and compute NNT. Is
there any information about Intention to Treat (ITT)
2–3 sentences
Note: this question pertains ONLY to Clinical Trials Outline
ITT, if information is provided
Score: 1 ¼ inadequate, raise doubts and concern,
2 ¼ adequate, but incomplete, 3 ¼ fine
C. Can the information provided in the paper be of any use
directly to any patient or the group of patients in your
practice, now?
2–3 sentences
Score: 1 ¼ inadequate, raise doubts and concern,
2 ¼ adequate, but incomplete, 3 ¼ fine
3. How
A. How was the question addressed from the perspective of
design, and were the appropriate caveats discussed?
2–3 Sentences
Note: distinguish between Prognostic/Diagnostic studies,
between observational (prospective, cross-sectional, case-
control) and experimental designs, and within these clinical
trials (run-in, cross-over, mixed). Note issues of randomization
and blinding (related to two of the Jadad queries). Note issues
of correct selection of the control and experimental groups
(threats to internal validity)
Score: 1 ¼ inadequate, raise doubts and concern,
2 ¼ adequate, but incomplete, 3 ¼ fine
B. How was the outcome measured, were issues of reliabil-
ity and validity presented?
2–3 sentences
Note: issues of selection of the instrument (threat of internal
validity) to measure the outcome variable under study; issue
of reliability (inter-rater, intra-rater, internal consistency)
and validity (criterion, content, construct) of measurement.
Score: 1 ¼ inadequate, raise doubts and concern,
2 ¼ adequate, but incomplete, 3 ¼ fine
C. How were the data presented and analyzed (SESTA)?
2–3 sentences
Note: refer to fundamental elements of SESTA below
Score: 1 ¼ inadequate, raise doubts and concern,
2 ¼ adequate, but incomplete, 3 ¼ fine
Note: Fundamental Elements of SESTA
What is the analysis meant to do?
Categorical versus Continuous Data; Comparison versus Pre-
diction; time series versus survival
Categorical Data Analysis
  Are categorical data, and only categorical data, analyzed
by the c
2–test? (y/n):
  Are the data matched categorical data and is the
McNemar c
2-test used? (y/n):
  Are the categorical data analyzed as a difference from
baseline, and therefore the Cochran Q c
2-test utilized?
(y/n):
  Are the categorical data analyzed from the perspective
of a prognostic stratifying variable, and is the Mantel-
Haenzel c
2-used? (y/n):
  Is the research design a 2 · 2 format and therefore uses
the Yates Correction for Continuity? (y/n):
  Are the E values (expected frequencies) >5, and therefore
the Fisher’s Exact test used? (y/n):
  Is collapsing performed judiciously, and does it involve
contiguous cells? (y/n):
  Is care given to avoid overly strong and absolute conclu-




  Are the assumptions for parametric statistics (i.e.
normality, independence, homogeneity of variance)
mentioned, tested, not violated? (y/n):
  If the assumptions are satisfied, are the data correctly
analyzed by a matched t-test? (y/n):
  If the assumptions are not satisfied, are the data correctly
analyzed by the Signed-Rank Wilcoxon/Mann–Whittney
U-test? (y/n):
  In the case of a comparison of only two groups with no
matching, if the assumptions are satisfied, are the data
correctly analyzed by a Student t-test? (y/n):
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groups, is the Ho ¨telling T
2-test presented? (y/n):
  If the assumptions are not satisfied, are the data correctly
analyzed by the Rank Sum Wilcoxon/Mann–Whitney
U-test? (y/n)
  If the assumptions are satisfied, and more than two
groups are studied, are the data correctly analyzed by
the analysis of variance (ANOVA)? (y/n):
  If the assumptions are not satisfied, then is a Geisser
Greenhouse correction presented? (y/n):
  Is one of the control variables used as a covariate—that is,
a variable that can vary together with the outcome
measure—and which ought to be used ’to correct meas-
urements of the outcome measure in order to obtain the
true and correct outcomes to be analyzed? (y/n):
  If the assumptions are satisfied, are the data correctly ana-
lyzed by the analysis of covariance (ANCOVA)? (y/n):
  If ANOVA or ANCOVA were performed, are ANOVA
or ANCOVA tables complete with sums of squares,
degrees of freedom, mean squares, F-values and P-values
presented? (y/n):
  OR are F statements not presented in the text with,
in brackets, the Fcrit value, degrees of freedom, and
P-value? [e.g. F(3.45), df ¼ 5; P ¼ 0.001] (y/n):
  OR are P-values not simply scattered in the text? (y/n):
  If a significant F-value is established by ANOVA or by
ANCOVA, are main effects and interactions tested by
pre hoc or by post hoc comparisons? (y/n):
  Was care taken in correcting the a level for the number of
repeated comparisons within the design by means of the
Bonferroni Correction—or any type of correction? (y/n):
  Upon performing post hoc comparisons, and drawing
conclusions from them, was care taken of usingthe appro-
priate test (e.g. comparing all the group means in the
design by the Scheffe’s test, comparing all possible pairs
of means of Tukey’s Honestly Significant Difference
test, comparing pairs of means following a ranking pro-
cess by using Newman-Keul’s test, comparing means
in a stepwise fashion to a reference control group with
Dunnett’s test)? (y/n):
  If the design involves more than two groups, but any one
of the three assumptions are not satisfied, does the design
involve one independent variable—‘one way’ and is
correctly analyzed by the Kruskal–Wallis test ? (y/n):
  OR does it involve two or more independent variables—
or one independent variable and one or more control vari-
ables, ‘factorial’ design—and is correctly analyzed by the
Friedman test? (y/n):
Continuous Data Analysis—Association and Prediction
  If the data presenting associations between two variables,
is the Pearson Correlation Coefficient correctly used
only when both variables are continuous? (y/n):
  Is the Spearman Rho correlation coefficient correctly
used when one of the two variables is categorical? (y/n):
  Is the Cohen k coefficient correctly computed and
discussed in the instance of agreement between two
observers along a binary—diseased/not diseased—
variable? (y/n):
  Are causal relationships not erroneously drawn from
correlations? (y/n):
  If the data is presented in a prediction model, are stand-
ardized regression coefficients shown as beta weights
and their statistical significance established? (y/n):
  Is the significance of the predictive model established by
means of ANOVA analysis? (y/n):
  Is the overall relationship among the predictors estab-
lished by the R
2 estimate? (y/n):
  In establishing the hierarchical predictive strength of each
predictor, is hierarchical or a stepwise regression model
adopted? (y/n):
  In the case of a binary—diseased/not diseased—non-
continuous outcome measure, is the logistic regression
model utilized? (y/n):
  Is the goodness-of-fit, the difference between observed
and fitted probabilities, presented and discussed? (y/n):
Time-Series and Survival Data
  If the data present time-related analyses, are these ana-
lyses short-term, and are the data analyzed correctly in a
ANOVA design that involves repeated measures? (y/n):
  OR, do the data relate to long-term time-series design,
and are presented by means of life tables, which are ana-
lyzed by means of the Kaplan–Meier, and the Cox
proportional hazard regression analysis? (y/n):
Overall Evaluation
2–3 paragraphs to highlight the strengths and weaknesses of
the paper and defend the overall critical evaluation and score.
Score
Each question is scored from 1 to 3. The total WWH score
ranges from 9–27 for Clinical Trials, and from 8–24 for studies
that are not Clinical Trials, and where the NNT does not apply
Appendix 2: EBR Recommendations in CAM
[adapted from (7)]
I. Clinical Relevance
(i) Determine whether or not a systematic review is relev-
ant to patient care
(ii) Establish a clearly defined and clinically relevant
research question expressed in terms of the rela-
tion between a CAM test intervention and a control
comparison
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(i) Explicitly define the inclusion and exclusion criteria
appropriate for identifying the studies used to answer
the clinical CAM question
(ii) Criteria optimally include the following:
randomized controlled trials (RCTs) and quais-RCTs
patient groups must pertain to the patient population
under study
interventions to be compared must relate to the study
question
studies identified in the search process must
present assessments of the outcome measure under
investigation
(iii) Establish a systematic search strategy for compre-
hensive sampling of available studies, which must
include foreign and non-customary bibliographic
databases [whether the inclusion of ‘gray’ literature
(i.e. non-peer-reviewed, public domain) is recom-
mendable or not is debatable because of potentially
unwise investment of resources]
III. Quality of the Evidence
(i) Characterize the threats to internal (i.e. replicability)
and to external validity of the study (i.e. generalizab-
ility) by means of research quality-rating scales (e.g.
Jadad, Wong, Timmer, Linde, GRADE)
(ii) Extract and tabulate data pertinent to meta-analysis
(e.g. group sample sizes, and means and standard
deviations of outcome under study)
(iii) Establish feasibility of meta-analysis by discussing
justification for statistical combination of the data
(i.e. similarities and differences among the studies
to be included in the meta-analysis)
IV. Evidence-Based Answer to Clinical Question
(i) Generate a consensus statement across the studies
analyzed that specifically addresses and answers the
research question, while clearly discusses the applica-
tions, implications and limitations of the findings
(ii) While systematic reviews are the best measures cur-
rently available to evaluate critically and to summarize
data and support the effectiveness and efficacy of ther-
apies, the success of this research lies in the stringent
adherence to its protocols
Appendix 3: The Markov Process
Clinical decision-making problems often involve multiple
transitions between health states. The probabilities of state
transitions, or related utility values, require complex computa-
tions over time. Neither decision trees nor traditional influence
diagrams offer as practical a solution as state of transition
models (i.e. Markov models). This is so because Markov mod-
els are designed to represent cyclical, recursive events,
whether short-term processes, and therefore are best used to
model prognostic clinical cases, such as a surgical procedure
and associated follow-up, or long-term management of a
chronic disease, such as Alzheimer’s disease, reliably and
accurately. Markov models can be used to calculate a
wide variety of outcomes, including average life expectancy,
expected utility, long-term costs of care, survival rate and
the number of recurrences.
Discrete Markov models enumerate a finite set of mutually
exclusive possible states so that, in any given time interval
(called a cycle or stage), an individual member of the Markov
cohort can be in only one of the states. In order to determine a
value for the entire process (e.g. a net cost or life expectancy),
a value (an incremental cost or utility) is assigned to each inter-
val spent in a particular state. The assignment of value in a
Markov model is called a reward, regardless of whether it
refers to a cost, utility or other attribute. A state reward refers
to a value that is assigned to the members of the cohort in a
particular state during a given stage. The actual values used
for state rewards depend on the attribute being calculated in
the model (e.g. cost, utility or life expectancy). A simple set
of initial probabilities is used to specify the distribution of
model subjects among the possible state rewards at the start
of the process. The resulting matrix of transition probabilities
is used to specify the transitions that are possible for the mem-
bers of each Markov reward state at the end of each successive
stage.
Two methods are commonly used to calculate the value of a
discrete Markov model: (i) cohort (expected value) calcula-
tions and (ii) Monte Carlo trials. In a cohort analysis, which
corresponds more realistically to a clinical situation, the
expected values of the process are computed by multiplying
the percentage of the cohort in a reward state by the incre-
mental value (i.e. cost or utility) assigned to that state. The out-
comes are added across all state rewards and all stages. In the
more theoretical Monte Carlo simulation trial, the incremental
values of the series of reward states traversed by the individual
are summed.
The Markov model is most often represented in a graphical
form known as a cycle tree. Since it is based on a node and
branch framework, it is easily integrated into standard decision
tree structures and can be appended to paths in a Markov
decision tree. The root node of the Markov cycle tree is called
a Markov node. Each of the possible health states is listed on
the branches emanating from the Markov node, with one
branch for each state. Possible state transitions are graphically
displayed on branches to the right. A state from which trans-
itions are not possible, such as the Dead state, is called an
absorbing state. No state rewards are given for being in the
Dead state, and zero values are assigned to the state rewards
of all absorbing states. In this fashion, the Markov process
integrates a termination condition, or stopping rule, specified
at the Markov node to determine whether a cohort analysis
is complete. This rule is the termination condition at the begin-
ning of each stage. When the termination condition is verified,
then the Markov process ends and the net reward(s) are
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conditions, which may be cumulative or alternative.
The Markov model generates an expected value analysis that
is performed at or to the left of each Markov node in cohort
analysis. The expected value analysis can generate additional
information about the Markov cohort calculations. For
example, in a model designed to measure the time spent in
the diseased state diagnosed as dementia of the Alzheimer’s
type, an expected value will be generated to average life
expectancy for a patient in the cohort. Additional calculated
values will include the amount of time spent, on average, in
each of the specified states of Alzheimer’s dementia. The per-
centage of the cohort in each state will be computed at the end
of the process. When the termination condition has been set to
continue the process until most of the cohort is absorbed into
the Dead state, the final probability of patients in the Dead
state will approach 1.0. In brief, one of the strongest assets of
the Markov model is its capacity to yield both an extensive
numerical description of the process under study as well as a
detailed graphical representation.
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